In the context of precision medicine, we evaluated a personalized treatment algorithm to guide the initial decision between these therapies.Using data from the observational Diabetes Prospective Follow-up registry (Germany/Austria) we studied individuals with T2D who initiated GLP-1-RA (n=1433) or SGLT2i (n=2547) in a multicenter, real-world setting. This evidence concerns the gene GLP1R and diabetes mellitus.